Staloral 300

Leaflet accompanying the packaging: patient information

STALORAL 300

Plant-based allergen extracts (plant pollen)
House dust mite allergen extracts
Allergen extract mixtures
Sublingual solution
10 IR/ml; 300 IR/ml

You should carefully read the contents of the leaflet before using the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if necessary.
• In case of any doubts, you should consult a doctor or pharmacist or nurse.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should inform their doctor, or pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is STALORAL 300 and what is it used for
• 2. Important information before using STALORAL 300
• 3. How to use STALORAL 300
• 4. Possible side effects
• 5. How to store STALORAL 300
• 6. Contents of the packaging and other information

1. What is STALORAL 300 and what is it used for

Specific immunotherapy medicine. It is used in patients allergic to plant-based allergens (plant pollen) or house dust mites, whose list is attached to this leaflet.

Indications for use

Allergic diseases of a seasonal or year-round nature, manifested by rhinitis (sneezing, runny nose or itchy nose, stuffy nose), conjunctivitis (itchy and watery eyes) or asthma (mild or moderate) in adults and children (over 5 years old).
The goal of treatment with STALORAL 300 is to increase immune tolerance to allergens, and thus alleviate allergic reactions.

2. Important information before using STALORAL 300

When not to use STALORAL 300

Only a doctor can determine if there are contraindications to the use of the medicine.

Warnings and precautions

Before starting treatment, symptoms of allergy should be stabilized with appropriate symptomatic treatment, if necessary.
Before starting treatment with STALORAL 300, the doctor or pharmacist should be informed:

STALORAL 300 and other medicines

The doctor should be told about all medicines taken recently, including those available without a prescription.
Before starting treatment, the doctor should be informed:

Symptomatic treatment (e.g., antihistamines and/or nasal corticosteroids) may be used concurrently with STALORAL 300.

Pregnancy and breastfeeding

Pregnant women, or women who suspect they are pregnant, or plan to become pregnant, should consult their doctor or pharmacist before using this medicine.
Breastfeeding women should consult their doctor or pharmacist before using this medicine.
There is no experience with the use of STALORAL 300 in pregnant or breastfeeding women, so immunotherapy should not be initiated in pregnant or breastfeeding women unless the doctor considers it necessary.
Women who become pregnant or start breastfeeding during treatment with STALORAL 300 should consult their doctor about continuing to take this medicine.

Driving and using machines

There are no contraindications to driving or using machines during treatment with STALORAL 300.

STALORAL 300 contains sodium chloride.

In the case of patients on a low-sodium diet, the presence of sodium chloride in the medicine should be taken into account (one 10 ml vial contains 590 mg of sodium chloride). See "Warnings and precautions".

3. How to use STALORAL 300

Recommended dose

STALORAL 300 should always be used in accordance with the doctor's recommendations. In case of doubts, you should contact your doctor or pharmacist again. In the event of using a higher dose of STALORAL 300 than recommended or missing a dose of STALORAL 300,
you should read the information in the relevant sections of the leaflet.
Specific immunotherapy is most effective when started in the early stages of the disease.
The dose size does not depend on age, but on the degree of individual patient reactivity.
In the case of seasonal allergies, it is recommended to start treatment before the pollen season and continue until the end of the pollen season.
In the case of year-round allergies, it is recommended to continue treatment throughout the year.
Treatment is divided into two stages:

• basic treatment - with gradual dose increase
• maintenance treatment - using a constant dose.

In treatment, allergen solutions of different concentrations are used, for which the packaging differs in cap color:
Cap color: blue - concentration 10 IR/ml
Cap color: purple - concentration 300 IR/ml

Basic treatment with dose increase

The medicine dose should be measured under the tongue by pressing the pump dispenser and after 2 minutes it should be swallowed.
The medicine is used daily, with each dose increased until the maintenance dose is reached according to the following scheme:

The above dosing scheme should be considered as a guideline and example of treatment. Treatment can be modified depending on the patient's condition and their reaction to treatment.

Maintenance treatment - constant dose

The maximum well-tolerated dose should be taken daily or three times a week.
The recommended dosing of the medicine is at least 4 presses 3 times a week or 2 to 4 presses taken daily, using a solution with a concentration of 300 IR/ml.
Clinical trials with the use of STALORAL 300 with various allergens have shown that a daily dose of 300 IR is well tolerated.

Duration of treatment

Usually, desensitization treatment is used for a period of 3 to 5 years.
The doctor will reassess the treatment in case of no significant improvement in symptoms after a year (year-round allergy) or after the first pollen season (seasonal allergy).

Method of administration

To ensure the safe use of the medicine, the doctor's recommendations should be strictly followed.
STALORAL 300 is administered sublingually.
Before taking the medicine, the information on the packaging should be carefully checked and it should be ensured that the data is consistent with the doctor's recommendation (prescription): patient's name, medicine composition and concentration, as well as the expiry date of the medicine.
The medicine should be taken during the day, to an empty stomach, without food and drink.
The medicine dose should be measured under the tongue by pressing the pump dispenser and after 2 minutes it should be swallowed.
The doctor may recommend a different dosing schedule depending on the patient's condition and their reaction to treatment.
STALORAL 300 should be administered to children by adults.
Guidelines for the first use of the medicine:
During the first use, the following points should be followed:

• 1. Remove the plastic, colored cap.
• 2. Pull the metal tab and completely remove the aluminum cap.
• 3. Remove the gray plug.
• 4. Remove the pump dispenser from the plastic cover. Place the vial on a flat surface, and then, holding it firmly with one hand, press the pump dispenser firmly into place.
• 5. Remove the purple protective ring.
• 6. Pump, repeating the presses of the pump dispenser. After 5 presses, the pump dispenser measures 1 full dose of the medicine.
• 7. Place the tip of the pump dispenser in the mouth, directly under the tongue. Press firmly to obtain a full dose. Repeat the action to obtain the number of doses prescribed by the doctor. Hold the solution under the tongue for 2 minutes and swallow.
• 8. After use, clean the tip of the pump dispenser and put the protective ring back on.
• 9. For subsequent uses, remove the protective ring and repeat steps 7 and 8.

7

Usually, desensitization treatment is used for 3 to 5 years. In the case of seasonal allergies, specific immunotherapy can be carried out for several seasons in subsequent years.

Use in children

Allergen immunotherapy is not recommended for children under 5 years old.

Using a higher dose of STALORAL 300 than recommended

The doctor or pharmacist should be informed immediately.
In the event of using a higher dose of the medicine than recommended, the risk of side effects increases or their severity may increase.

Missing a dose of STALORAL 300

A double dose should not be used to make up for a missed dose.
Treatment should be continued the next day, taking the established dose.

Discontinuing STALORAL 300

If the medicine is discontinued for less than a week, treatment can be continued using the last dose. If treatment is discontinued for more than a week, the doctor should be consulted.
In case of any further doubts related to the use of this medicine, the doctor or pharmacist or nurse should be consulted.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
During treatment with STALORAL 300, the patient will be exposed to the action of substances that can cause allergic reactions at the site of administration and/or symptoms that can affect the whole body.
Such reactions may occur at the start of treatment or later, during treatment.

The following symptoms should be reported to a doctor immediately:

Severe allergic reaction with rapid onset of symptoms, which affects the whole body, e.g. intense itching or rash, difficulty breathing, abdominal pain, or symptoms related to low blood pressure, such as dizziness, malaise.
Tolerance to a given dose may change over time depending on the patient's health and environment.
In the event of a side effect, the doctor should be consulted, who may change the treatment schedule.
The doctor may prescribe pre-treatment with antiallergic medicines to reduce the frequency and severity of side effects.

Additional side effects

Frequent (affecting less than 1 in 10 patients)
Mouth disorders (e.g., swelling, discomfort, tingling, itching, numbness, blisters, ulcers), tongue swelling, discomfort in the throat or pain or swelling or irritation,
rhinitis (stuffy nose, runny nose, sneezing, itchy nose, discomfort in the nose), cough,
salivary gland disorders, itchy eyes, itchy ears, nausea, vomiting, abdominal pain, diarrhea, skin redness or itching.
Uncommon (affecting less than 1 in 100 patients)
Eye disorders (redness, irritation of the eyes, watery eyes), herpes, hoarseness, breathing difficulties, asthma, hives, atypical skin allergy symptoms (burning, tingling, stinging), gastritis, esophageal spasms.
Rare (affecting less than 1 in 1000 patients)
Headache, eczema, joint pain, muscle pain, weakness, enlarged lymph nodes (glands), fever.
The following side effects have also been reported:
Taste disorders, dry mouth, dizziness, facial swelling, severe allergic reactions, esophagitis.

Reporting side effects

If any side effects occur, including any side effects not listed in the leaflet, the doctor or pharmacist or nurse should be informed. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel. 22 49 21 301, fax 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.

5. How to store STALORAL 300

The medicine should be stored in a place invisible and inaccessible to children.
Before opening: Store in a refrigerator (2°C - 8°C).
After opening:
10 IR/ml: Store in a refrigerator (2°C - 8°C) for up to 30 days.
300 IR/ml: Store at a temperature below 25°C for up to 30 days or in a refrigerator (2°C - 8°C) for up to 30 days.
During transport, the vials should always be carried in a vertical position.
The medicine should not be used for more than 30 days after opening and after the expiry date stated on the packaging after the "EXP" expiry date. The expiry date refers to the last day of the given month.
Medicines should not be disposed of in wastewater or household waste. The pharmacist should be asked how to dispose of medicines that are no longer used. This will help protect the environment.

6. Contents of the packaging and other information

What does STALORAL 300 contain

The active substance of the medicine is allergen extracts or their mixtures with a concentration of 10 or 300 IR/ml (according to annex 1) in combination with mannitol. The amount of mannitol does not exceed 40 mg/ml.
The qualitative composition of the active substance may be individually selected for the patient within the range of allergens listed in annex 1.
The activity of the relevant allergen expressed in IR units/ml is given on the label.
* IR (reactivity index): the allergen extract has an activity equal to 100 IR/ml if it causes a redness with a diameter of 7mm in a skin prick test using a Stallerpoint needle in 30 people allergic to the given allergen.
The sensitivity of the tested persons is also confirmed by a positive reaction to 9% codeine phosphate or 10 mg/ml histamine dihydrochloride in a skin prick test.
Other ingredients are: sodium chloride, glycerol, purified water

What does STALORAL 300 look like and what does the packaging contain

Basic treatment kit:
3 vials of 10 ml (concentration 10 IR/ml, concentration 300 IR/ml, concentration 300 IR/ml)
+ 3 pump dispensers
Maintenance treatment kit:
2 vials of 10 ml (concentration 300 IR/ml, concentration 300 IR/ml)
+ 2 pump dispensers

Marketing authorization holder and manufacturer

STALLERGENES
6, rue Alexis de Tocqueville
92160 Antony, France
To obtain more detailed information, you should contact the representative of the marketing authorization holder in Poland:
STALLERGENES Sp. z o.o.
tel. 22 620 29 98
Date of last update of the leaflet: 02/2024

STALORAL 300

ANNEX 1

I. PLANT-BASED ALLERGEN EXTRACTS (PLANT POLLEN)

Grasses and cereals:

661Timothy grass (Phleum pratense)

Trees:

609Black alder (Alnus glutinosa)
615White birch (Betula alba)
651European olive tree (Olea europea)
649Hazel (Corylus avellana)

II. HOUSE DUST MITE ALLERGEN EXTRACTS

315Dermatophagoides pteronyssinus
314Dermatophagoides farinae

III. ALLERGEN EXTRACT MIXTURES

Plant-based:

6885 grasses (meadow fescue, sweet vernal grass, perennial ryegrass, meadow grass, timothy grass)

House dust mites:

350Dermatophagoides pteronyssinus, Dermatophagoides farinae